Bristol Myers Squibb Stock - Weekly review and sector comparison after a quiet news week
19.06.2026 - 21:53:16 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 19:52 UTC. Details in the imprint.
Bristol Myers Squibb (US0897961004) remains without major fresh corporate headlines in the past few days. In this quiet phase, the spotlight shifts to how the large-cap pharma stock has fared over the latest week relative to peers and benchmarks.
All news and key data on Bristol Myers Squibb stock
Track recent headlines, financial data and regulatory filings for Bristol Myers Squibb stock on one dedicated page.
How the shares performed this week
On Thursday, 06/18/2026, Bristol Myers Squibb shares closed at $54.10 on the New York Stock Exchange, edging up 0.19% on the day, according to MarketBeat's end-of-day data. After-hours trading saw a marginal move to $54.07.
Over the latest week, the stock spent time around the mid-$50 range, a level that leaves it below many analyst price targets but within the recent trading corridor seen since spring. Trading volumes stayed close to normal levels, signaling neither strong accumulation nor capitulation.
Position versus pharma and wider market
With a market capitalization around $110 billion at a recent quote of roughly $54 per share, Bristol Myers Squibb remains one of the larger global biopharma names. This size puts the company in the heavyweight bracket of US healthcare, alongside Pfizer and Merck.
Sector-wide, large pharma stocks have traded in a mixed fashion this week as investors balanced defensive cash flows with ongoing patent-expiry risks. Against that backdrop, Bristol Myers Squibb's relatively stable share price underscores a muted but steady stance in the peer group.
Analyst sentiment and valuation snapshot
Recent aggregated analyst data point to an average price target near $62 for Bristol Myers Squibb, implying upside from the latest $54 level. The consensus rating clusters around a Hold signal, reflecting a balanced view of pipeline opportunities and patent headwinds.
Valuation metrics remain moderate compared with some faster-growing biotech names, with a trailing price-to-earnings ratio in the mid-teens. For many investors, the stock therefore represents a classic large-cap pharma holding with income and pipeline optionality rather than a high-growth bet.
What the company sells
Bristol Myers Squibb generates most of its revenue from prescription medicines in oncology, hematology, immunology and cardiovascular disease. Flagship products include the cancer drug Opdivo and the anticoagulant Eliquis, both of which are key drivers of cash flow and R&D reinvestment.
Where the stock trades today
The shares of Bristol Myers Squibb (US0897961004) last traded on the New York Stock Exchange at $54.10 as of 06/18/2026, 15:59 Eastern Time.
Key facts on Bristol Myers Squibb stock
- Company: Bristol-Myers Squibb Company
- ISIN: US0897961004
- WKN: 850501
- Ticker: BMY
- Venue: NYSE
- Price (as of 06/18/2026, 15:59 Eastern Time): 54.10 USD
- Market cap: 110,310,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
